Literature DB >> 6488689

Phenotypic consistency in hydroxylation of desmethylimipramine and debrisoquine in healthy subjects and in human liver microsomes.

E Spina, C Birgersson, C von Bahr, O Ericsson, B Mellström, E Steiner, F Sjöqvist.   

Abstract

The 2-hydroxylation of desmethylimipramine (DMI) and the 4-hydroxylation of debrisoquine (D) were studied in healthy subjects and in human liver microsomes. A single oral dose of DMI (25 mg) was given to 18 healthy subjects previously phenotyped with D (13 rapid and five slow hydroxylators). Urine was collected for 24 hr and DMI and total 2-hydroxydesmethylimipramine (2-OH-DMI) levels were determined by HPLC. The urinary ratio DMI/2-OH-DMI correlated strongly (r = 0.92) with the urinary ratio of D to 4-hydroxydebrisoquine (D/4-OH-D). The two hydroxylations were also studied in human liver microsomes from 10 different subjects. Formation rates of the hydroxylated metabolites correlated strongly (r = 0.869). Moreover, D competitively inhibited the 2-hydroxylation of DMI. These findings suggest that both are hydroxylated by the same cytochrome P-450 isozyme.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6488689     DOI: 10.1038/clpt.1984.239

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  21 in total

1.  Clomipramine metabolism. Model-based analysis of variability factors from drug monitoring data.

Authors:  M Gex-Fabry; A E Balant-Gorgia; L P Balant; G Garrone
Journal:  Clin Pharmacokinet       Date:  1990-09       Impact factor: 6.447

2.  Difference in desipramine metabolic profile between wild-type and CYP2D6-humanized mice.

Authors:  Hong-Wu Shen; Ai-Ming Yu
Journal:  Drug Metab Lett       Date:  2009-12

3.  Phenacetin O-deethylase: an activity of a cytochrome P-450 showing genetic linkage with that catalysing the 4-hydroxylation of debrisoquine?

Authors:  G C Kahn; A R Boobis; M J Brodie; E L Toverud; S Murray; D S Davies
Journal:  Br J Clin Pharmacol       Date:  1985-07       Impact factor: 4.335

4.  Tolbutamide 4-hydroxylase activity of human liver microsomes: effect of inhibitors.

Authors:  H S Purba; D J Back; M L Orme
Journal:  Br J Clin Pharmacol       Date:  1987-08       Impact factor: 4.335

5.  Imipramine metabolism in relation to the sparteine and mephenytoin oxidation polymorphisms--a population study.

Authors:  H Madsen; K K Nielsen; K Brøsen
Journal:  Br J Clin Pharmacol       Date:  1995-04       Impact factor: 4.335

6.  Interindividual variability in the N-sulphation of desipramine in human liver and platelets.

Authors:  P Romiti; L Giuliani; G M Pacifici
Journal:  Br J Clin Pharmacol       Date:  1992-01       Impact factor: 4.335

7.  Steady-state concentrations of imipramine and its metabolites in relation to the sparteine/debrisoquine polymorphism.

Authors:  K Brøsen; R Klysner; L F Gram; S V Otton; P Bech; L Bertilsson
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 8.  Active hydroxymetabolites of antidepressants. Emphasis on E-10-hydroxy-nortriptyline.

Authors:  C Nordin; L Bertilsson
Journal:  Clin Pharmacokinet       Date:  1995-01       Impact factor: 6.447

9.  Polymorphic 2-hydroxylation of desipramine. A population and family study.

Authors:  M L Dahl; L Iselius; C Alm; J O Svensson; D Lee; I Johansson; M Ingelman-Sundberg; F Sjöqvist
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

10.  Importance of oxidative polymorphism and levomepromazine treatment on the steady-state blood concentrations of clomipramine and its major metabolites.

Authors:  A E Balant-Gorgia; L P Balant; C Genet; P Dayer; J M Aeschlimann; G Garrone
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.